Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases

Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases

US Patent 9713614 · Granted Jul 25, 2017

Estimated economic value: $23,788,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Pyrazolone-derivatives and their use as PDE-4 inhibitors2016
Pyrazolone-derivatives and their use as PDE-4 inhibitors2016
Pyrazolone derivatives as PDE4 inhibitors2015
Pyrazolone derivatives as PDE4 inhibitors2015
3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives2015
3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives2015
Pyrazolone derivatives as PDE4 inhibitors2014
Pyrazolone derivatives as PDE4 inhibitors2014
Roflumilast for the treatment of pulmonary hypertension2014
Pyrazolone-derivatives and their use as PDE-4 inhibitors2013
Pyrazolone-derivatives and their use as PDE-4 inhibitors2013
Use of the combination of ciclesonide and antihistamines for the treatment of al2013